HIF-2α PAS-B Domain Cavity Targeting for Selective Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for advanced metastatic cancer lack effective targeting of hypoxic cancer cells, particularly those involving HIF-2α, due to the difficulty in disrupting the large dimerization interfaces like the HLH-PAS-B domains of HIF2α and HIF1β, and existing drugs have limited efficacy and specificity.
Innovation Solution
Development of specific small molecules that bind to the HIF-2α PAS-B domain cavity, inhibiting its heterodimerization with HIF1β without affecting HIF1α, thereby disrupting the transcriptional activity of HIF2α without interfering with HIF1α's dimerization, using compounds of formula (I) and their pharmaceutically acceptable salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing drugs are used to target HIF-2α, then tumor growth inhibition is achieved, but specificity is poor due to inability to distinguish HIF-2α from HIF-1α
Solution Approach 1:
The patent applies local quality by targeting a specific local region (PAS-B domain cavity) of HIF-2α that is structurally distinct from HIF-1α. The small molecules are designed to fit specifically into this localized cavity, exploiting subtle structural differences in the binding pocket to achieve selective inhibition of HIF-2α while sparing HIF-1α, thereby improving specificity and reducing off-target effects.
Solution Approach 2:
The patent employs asymmetry by designing molecules that exploit the asymmetric structural differences between HIF-1α and HIF-2α PAS-B domains. The compounds are configured to match the unique asymmetric features of the HIF-2α binding cavity, including specific amino acid residues and cavity geometry, enabling selective recognition and binding only to HIF-2α.
2Reliability
If small molecules are designed to disrupt HIF-2α dimerization, then transcriptional activity is inhibited, but the large dimerization interface makes binding difficult
Solution Approach 1:
The patent applies the taking out principle by extracting a specific accessible sub-region (PAS-B domain cavity) from the large HLH-PAS-B dimerization interface. Instead of attempting to block the entire extensive dimerization interface, the invention isolates and targets a specific cavity within the PAS-B domain that is more accessible to small molecules, thereby achieving effective inhibition with simpler, more druggable binding sites.
Solution Approach 2:
The patent segments the large HLH-PAS-B dimerization interface into distinct functional regions, specifically targeting the PAS-B domain cavity as a separate druggable unit. This segmentation allows small molecules to bind to a discrete, accessible pocket rather than requiring simultaneous interaction with multiple residues across the entire dimerization interface, simplifying the binding mechanism.
3Object-affected harmful factors
If broad HIF inhibition is used, then tumor angiogenesis is suppressed, but normal oxygen regulation is disrupted
Solution Approach 1:
The patent applies local quality by selectively targeting only the HIF-2α pathway through its unique PAS-B domain cavity, while leaving the HIF-1α pathway intact. This localized targeting allows suppression of pathological angiogenesis driven by HIF-2α in tumors while preserving the physiological oxygen sensing and regulation functions mediated by HIF-1α in normal tissues.
Solution Approach 2:
The patent uses the PAS-B domain cavity as an intermediary binding site that mediates selective inhibition. The small molecules bind to this intermediary cavity in HIF-2α, which serves as a unique access point that does not interfere with the separate dimerization and DNA binding functions of HIF-1α, thereby allowing selective pathway inhibition.
Data Source
AI summary
Provided is a method of inhibiting heterodimerization of HIF-2α to HIF1β (ARNT) comprising binding certain small molecules to the HIF-2α PAS-B domain cavity but not to HIF1α and inhibiting HIF-2α heterodimerization to HIF1β (ARNT) but not inhibiting HIF1α heterodimerization to HIF1β (ARNT). Those certain small molecules are also referenced synonymously as HIF2-HDI and HIF2α heterodimerization inhibitors and also simply as certain small molecules.